Astragaloside IV alleviates sepsis-induced muscle atrophy by inhibiting the TGF-β1/Smad signaling pathway
International Immunopharmacology · 2023-02 · 115 · 109640
DOI: 10.1016/j.intimp.2022.109640 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-02. Verfasst von Hongkai Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Sepsis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND: Muscle atrophy occurs in patients with sepsis and increases mortality and disability. Remission of muscle atrophy may improve the quality of life in patients with sepsis. Astragaloside IV (ASIV) has been shown to have excellent anti-inflammatory and anti-fibrotic effects and to reduce organ damage caused by sepsis. However, the effect of ASIV on sepsis-induced muscle atrophy has not been reported. Therefore, this study explored the pharmacological effects and mechanisms of ASIV in sepsis-induced muscle atrophy. METHODS: Cecal ligation and puncture (CLP) was used to establish a mouse model of sepsis and lipopolysaccharide (LPS)-stimulated C2C12 myotubes. After administration of ASIV, the body weight, tibialis anterior (TA) and gastrocnemius muscle weight and fiber cross-sectional area of the mice were measured. The diameter of myotubes was observed by immunofluorescence staining. ELISA was used to assess inflammatory factors in plasma and cell culture supernatants. RT-PCR and Western blotting were used to detect the expression of MuRF1, Atrogin-1 and TGF-β1/Smad signaling pathway components in TA and C2C12 myotubes. RESULTS: Our study found that ASIV reduced serum inflammatory factors and improved survival in septic mice. ASIV alleviated muscle mass reduction, myofiber cross-sectional area reduction, and C2C12 myotube atrophy by inhibiting the expression of the E3 ubiquitin ligases MuRF1 and atrogin-1. In addition, we observed that ASIV inhibited TGF-β1/Smad signaling. Inhibition of the TGF-β1/Smad signaling pathway partly blocked the anti-muscle atrophy effect of ASIV. CONCLUSION: ASIV can alleviate sepsis-induced muscle atrophy, which may be related to the inhibition of the TGF-β1/Smad signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huaz…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dai, H., Zheng, Y., Chen, R., Wang, Y., Zhong, Y., Zhou, C., Zhan, C., & Luo, J. (2023). Astragaloside IV alleviates sepsis-induced muscle atrophy by inhibiting the TGF-β1/Smad signaling pathway. International Immunopharmacology, 115, 109640. https://doi.org/10.1016/j.intimp.2022.109640
Vancouver
Dai H, Zheng Y, Chen R, Wang Y, Zhong Y, Zhou C, et al. Astragaloside IV alleviates sepsis-induced muscle atrophy by inhibiting the TGF-β1/Smad signaling pathway. International Immunopharmacology. 2023;115:109640. doi:10.1016/j.intimp.2022.109640
BibTeX
@article{Dai2023,
author = {Dai, Hongkai and Zheng, Yingfang and Chen, Renyu and Wang, Yurou and Zhong, Yanxia and Zhou, Chenchen and Zhan, Chengye and Luo, Jinlong},
title = {Astragaloside IV alleviates sepsis-induced muscle atrophy by inhibiting the TGF-β1/Smad signaling pathway},
journal = {International Immunopharmacology},
year = {2023},
volume = {115},
pages = {109640},
doi = {10.1016/j.intimp.2022.109640}
}
EUVIMED